Lion TCR Secures USD 40 million Series B2 Financing, Revolutionizing Solid Tumor Treatment with mRNA-Encoding TCR-T Cell Therapy

27 June 2023, Lion TCR, a clinical-stage T-cell immunotherapy company, is thrilled to announce the successful completion of its USD 40 million Series B2 financing round. Guangzhou Industrial Investment and Capital Operation Holding Group Ltd. led the financing with participation from Guangzhou Guoju Investment and CSPC NARD Capital Fund. The funds raised will be used primarily to support Lion TCR's clinical trials on hepatitis B virus (HBV)-specific TCR T cell therapy, while also facilitating th

Related Keywords

Guangzhou ,Guangdong ,China ,Singapore ,Macao ,Macau General ,Macau ,Hong Kong ,Israel ,Jilin ,Chinese ,Peng Xiaoming ,Biopharmaceutical Industry Fund ,Guangzhou Innovation Investment Fund ,Oriza Holdings ,Guangdong Traditional Chinese Medicine Health Fund It ,Chinese Service Enterprises ,Capital Fund ,Hong Kong Stock Exchange ,Drug Administration ,Yuexiu Enterprises Holdings Ltd ,Guangzhou Industrial Investment Fund ,Guoxin Securities Co Ltd ,Israel Phase Ii Fund ,Tech Investment Group Co Ltd ,Guangzhou Pharmaceutical Group ,Chinese Enterprises ,Capital Operation Holding Group Ltd ,Guangzhou Automobile Group ,About Lion ,Fast Track Designation ,Orphan Drug Designation ,Macao Greater Bay ,Huangpu District Government ,China Singapore Guangzhou Knowledge ,Guangzhou Industrial Investment ,Capital Operation Holding Group ,Industrial Investment ,Yuexiu Enterprises ,Guoju Investment ,Industry Fund ,Israel Phase ,Traditional Chinese Medicine Health Fund ,Jingwei Venture Capital ,Sequoia Capital China ,Guangzhou Guoju Investment ,Clinical Trials ,Uangpu District Government Of Guangzhou ,Cell Therapy ,Bion ,